When should rivaroxaban (Xarelto) be held before an elective upper endoscopy, and is any heparin bridging required?

Management of Rivaroxaban (Xarelto) for Upper Endoscopy

For diagnostic upper endoscopy without planned intervention, omit the morning dose of rivaroxaban on the day of the procedure; for therapeutic upper endoscopy with high bleeding risk (such as polypectomy, variceal banding, or dilation), hold rivaroxaban for 3 days (last dose taken 3 days before the procedure), and do not use heparin bridging. 1

Risk Stratification of Upper Endoscopy Procedures

Upper endoscopy procedures must first be classified by bleeding risk to determine the appropriate management strategy:

Low bleeding risk procedures (continue or minimal interruption):

• Diagnostic esophagogastroduodenoscopy with biopsy 1
• Endoscopic ultrasound without fine needle aspiration 1

High bleeding risk procedures (require 3-day interruption):

• Polypectomy 1
• Variceal injection or banding 1
• Dilation of strictures 1
• Endoscopic ultrasound with fine needle aspiration 1
• Percutaneous endoscopic gastrostomy placement 1

Timing of Rivaroxaban Discontinuation

For Low-Risk Diagnostic Upper Endoscopy

Simply omit the morning dose of rivaroxaban on the day of the procedure 1. The 2021 BSG/ESGE guidelines support this minimal interruption approach based on the PAUSE trial, which demonstrated low rates of major bleeding and thromboembolism with this strategy 1.

Alternatively, if desired for additional safety margin, you may hold rivaroxaban for 1 full day (last dose taken 2 days before the procedure), though this is not mandatory for low-risk procedures 1.

For High-Risk Therapeutic Upper Endoscopy

The last dose of rivaroxaban should be taken 3 days before the procedure 1. This means the patient takes no rivaroxaban for 2 full days plus omits the dose on the day of the procedure, allowing approximately 4-5 half-lives for drug elimination 1.

The 2021 BSG/ESGE guidelines provide a strong recommendation for this 3-day interruption based on evidence from the PAUSE trial, which included 3,007 patients and demonstrated low rates of major bleeding (1.35%) and arterial thromboembolism (0.16%) with standardized interruption protocols 1.

Special Considerations for Renal Function

Rivaroxaban timing remains the same (3 days for high-risk procedures) regardless of kidney function, as long as creatinine clearance is >30 mL/min 2. Unlike dabigatran, rivaroxaban undergoes dual hepatic and renal elimination (approximately 33% renal), making it less dependent on renal function for clearance 1, 3.

However, if a patient on rivaroxaban has rapidly deteriorating renal function, consult a hematologist before proceeding 1.

Bridging Anticoagulation: Not Recommended

Do not use heparin bridging (either unfractionated heparin or low-molecular-weight heparin) when holding rivaroxaban for endoscopy 1, 2. Multiple high-quality guidelines explicitly state that bridging significantly increases major hemorrhage rates (2.7% vs 0.5%, p=0.01) without reducing thromboembolism 1.

The 2021 BSG/ESGE guidelines note that in the RE-LY trial, bridging of DOACs with LMWH resulted in higher major hemorrhage rates (6.5% vs 1.8%, p<0.001) with no difference in thrombosis rates 1. A Japanese study of 16,977 patients demonstrated significant increases in both postprocedure GI bleeding and thromboembolism in patients who were bridged with heparin 1.

The only exception where bridging might be considered is for warfarin in patients with mechanical heart valves—this does not apply to rivaroxaban 1.

Resumption of Rivaroxaban After Endoscopy

Restart rivaroxaban 2-3 days after high bleeding risk procedures once adequate hemostasis is established 1. For low bleeding risk procedures, rivaroxaban may be resumed 1 day after the procedure 1.

The FDA label states that rivaroxaban should be restarted "as soon as adequate hemostasis has been established," noting the short time to onset of therapeutic effect 4.

Resume at the patient's usual maintenance dose—do not use loading doses or altered dosing 2.

Practical Implementation Algorithm

1. Classify the procedure:

   • Diagnostic EGD with biopsy = low risk
   • Therapeutic intervention (polypectomy, variceal treatment, dilation, PEG) = high risk 1

2. For low-risk procedures:

   • Omit morning dose on procedure day 1
   • Resume rivaroxaban 1 day post-procedure 1

3. For high-risk procedures:

   • Last dose 3 days before procedure 1
   • No heparin bridging 1
   • Resume 2-3 days post-procedure once hemostasis confirmed 1

4. Check renal function:

   • If CrCl >30 mL/min: standard 3-day hold 2
   • If rapidly deteriorating renal function: consult hematology 1

Common Pitfalls to Avoid

Do not use INR or aPTT to monitor rivaroxaban activity—these tests are unreliable indicators of anticoagulant effect from direct oral anticoagulants 1. If confirmation of drug clearance is needed, anti-Factor Xa chromogenic assays can be used, though this is rarely necessary 5.

Do not bridge with heparin products—this is the most critical error to avoid, as it dramatically increases bleeding risk without benefit 1, 2.

Do not confuse the timing for dabigatran with rivaroxaban—dabigatran requires longer interruption periods (5 days) in patients with reduced renal function (CrCl 30-50 mL/min), but rivaroxaban does not 1.

Ensure the patient understands "3 days before" means the last dose is taken 3 days prior—provide written instructions specifying the exact date and time of the last dose 2.

Do not resume rivaroxaban too early after high-risk procedures—wait for confirmed hemostasis and 2-3 days post-procedure to minimize bleeding complications 1.